Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer

1. Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).

   Google Scholar 

2. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

   Google Scholar 

3. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).

   Google Scholar 

4. Mullard, A. FDA approves first CAR T therapy. Nat. Rev. Drug Discov. 16, 669 (2017).

   Google Scholar 

5. Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).

   Google Scholar 

6. Xia, L. et al. Targeting triple-negative breast cancer with combination therapy of EGFR CAR T cells and CDK7 inhibition. Cancer Immunol. Res. 9, 707–722 (2021).

   Google Scholar 

7. Stüber, T. et al. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J. Immunother. Cancer 8, e000676 (2020).

   Google Scholar 

8. Erler, P. et al. Multi-armored allogeneic MUC1 CAR T cells enhance efficacy and safety in triple-negative breast cancer. Sci. Adv. 10, eadn9857 (2024).

   Google Scholar 

9. Raj, D. et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut 68, 1052–1064 (2019).

   Google Scholar 

10. Li, N. et al. The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nat. Commun. 14, 1986 (2023).

    Google Scholar 

11. Yuan, Y. et al. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. Transl. Oncol. 39, 101803 (2024).

    Google Scholar 

12. Ghasempour, S. & Freeman, S. A. The glycocalyx and immune evasion in cancer. FEBS J. https://doi.org/10.1111/febs.16236 (2021).

13. Öhlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503–1523 (2014).

    Google Scholar 

14. Connor, A. A. & Gallinger, S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat. Rev. Cancer 22, 131–142 (2022).

    Google Scholar 

15. Kankeu Fonkoua, L. A., Sirpilla, O., Sakemura, R., Siegler, E. L. & Kenderian, S. S. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol. Ther. 25, 69–77 (2022).

    Google Scholar 

16. Beatson, R. et al. The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. Nat. Immunol. 17, 1273–1281 (2016).

    Google Scholar 

17. Park, S. et al. Immunoengineering can overcome the glycocalyx armour of cancer cells. Nat. Mater. 23, 429–438 (2024).

    Google Scholar 

18. Gubbels, J. A. A. et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 9, 11 (2010).

    Google Scholar 

19. Pedram, K. et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat. Biotechnol. https://doi.org/10.1038/s41587-023-01840-6 (2023).

20. Park, S. et al. Leucine zipper-based SAIM imaging identifies therapeutic agents to disrupt the cancer cell glycocalyx for enhanced immunotherapy. Preprint at https://doi.org/10.1101/2024.12.05.627089 (2024).

21. Park, S. et al. Collagen mineralization decreases NK cell-mediated cytotoxicity of breast cancer cells via increased glycocalyx thickness. Adv. Mater. 2311505 https://doi.org/10.1002/adma.202311505 (2024).

22. Hollander, E. E. et al. N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance. JCI Insight 9, e178804 (2024).

    Google Scholar 

23. Posey, A. D. et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 44, 1444–1454 (2016).

    Google Scholar 

24. Supimon, K. et al. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma. Sci. Rep. 11, 6276 (2021).

    Google Scholar 

25. Mei, Z. et al. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med. 9, 640–652 (2020).

    Google Scholar 

26. Zhou, R. et al. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front. Immunol. 10, 1149 (2019).

    Google Scholar 

27. Yazdanifar, M. et al. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells 8, 1070 (2019).

    Google Scholar 

28. Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901–4909 (2008).

    Google Scholar 

29. Van Elssen, C. H. M. J. et al. Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57, 597–606 (2010).

    Google Scholar 

30. Cloosen, S. et al. Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma. Br. J. Haematol. 135, 513–516 (2006).

    Google Scholar 

31. Andrulis, M. et al. Expression of Mucin-1 in multiple myeloma and its precursors: correlation with glycosylation and subcellular localization. Histopathology 64, 799–806 (2014).

    Google Scholar 

32. Gutierrez, R. et al. Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors. JCO 39, e14513–e14513 (2021).

    Google Scholar 

33. Greco, B. et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci. Transl. Med. 14, eabg3072 (2022).

    Google Scholar 

34. Zhou, J. Y. & Cobb, B. A. Glycans in immunologic health and disease. Annu. Rev. Immunol. 39, 511–536 (2021).

    Google Scholar 

35. Costa, C. et al. Abnormal protein glycosylation and activated PI3K/Akt/mTOR pathway: role in bladder cancer prognosis and targeted therapeutics. PLoS ONE 10, e0141253 (2015).

    Google Scholar 

36. Davidson, B. et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Hum. Pathol. 31, 1081–1087 (2000).

    Google Scholar 

37. Springer, G. F., Desai, P. R. & Banatwala, I. Blood group MN antigens and precursors in normal and malignant human breast glandular tissue. J. Natl. Cancer Inst. 54, 335–339 (1975).

    Google Scholar 

38. Zhang, S. et al. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4, 295–302 (1998).

    Google Scholar 

39. Remmers, N. et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 19, 1981–1993 (2013).

    Google Scholar 

40. Ohshio, G. et al. Distribution of Tn antigen recognized by an anti-Tn monoclonal antibody (MLS128) in normal and malignant tissues of the digestive tract. J. Cancer Res. Clin. Oncol. 121, 247–252 (1995).

    Google Scholar 

41. López-Ferrer, A., Barranco, C. & de Bolós, C. Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma. Am. J. Clin. Pathol. 118, 749–755 (2002).

    Google Scholar 

42. Sun, X., Ju, T. & Cummings, R. D. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer 18, 827 (2018).

    Google Scholar 

43. Ju, T. & Cummings, R. D. A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase. Proc. Natl. Acad. Sci. USA 99, 16613–16618 (2002).

    Google Scholar 

44. Ju, T. et al. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 68, 1636–1646 (2008).

    Google Scholar 

45. Schietinger, A. et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 314, 304–308 (2006).

    Google Scholar 

46. Ju, T. & Cummings, R. D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252 (2005).

    Google Scholar 

47. Nogimori, K. et al. Increased expression levels of ppGalNAc-T13 in lung cancers: Significance in the prognostic diagnosis. Int. J. Oncol. 49, 1369–1376 (2016).

    Google Scholar 

48. Huang, M.-J. et al. Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling. Oncotarget 6, 5650–5665 (2015).

    Google Scholar 

49. Park, J.-H. et al. Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70, 2759–2769 (2010).

    Google Scholar 

50. Wang, Z.-Q. et al. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget 5, 544–560 (2014).

    Google Scholar 

51. Taniuchi, K. et al. Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene 30, 4843–4854 (2011).

    Google Scholar 

52. Ju, T., Aryal, R. P., Kudelka, M. R., Wang, Y. & Cummings, R. D. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 14, 63–81 (2014).

    Google Scholar 

53. Babino, A. et al. Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis. Int. J. Cancer 86, 753–759 (2000).

    Google Scholar 

54. O’Connor, J. C., Julian, J., Lim, S. D. & Carson, D. D. MUC1 expression in human prostate cancer cell lines and primary tumors. Prostate Cancer Prostatic Dis. 8, 36–44 (2005).

    Google Scholar 

55. Walsh, M. D., Luckie, S. M., Cummings, M. C., Antalis, T. M. & McGuckin, M. A. Heterogeneity of MUC1 expression by human breast carcinoma cell lines in vivo and in vitro. Breast Cancer Res. Treat. 58, 255–266 (1999).

    Google Scholar 

56. Hirabayashi, K. et al. Dual targeting CAR-T cells with optimal costimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors. Nat. Cancer 2, 904–918 (2021).

    Google Scholar 

57. Haubner, S. et al. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell 41, 1871–1891.e6 (2023).

    Google Scholar 

58. Katsarou, A. et al. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Sci. Transl. Med. 13, eabh1962 (2021).

    Google Scholar 

59. Hassan, R. et al. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin. Cancer Res. 12, 4983–4988 (2006).

    Google Scholar 

60. Mack, M., Riethmüller, G. & Kufer, P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. USA 92, 7021–7025 (1995).

    Google Scholar 

61. Boucher, J. C. et al. CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunol. Res. 9, 62–74 (2021).

    Google Scholar 

62. Li, C.-L. et al. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy. Biomed. Pharmacother. 154, 113616 (2022).

    Google Scholar 

63. Van Cauteren, H., Heykants, J., De Coster, R. & Cauwenbergh, G. Itraconazole: pharmacologic studies in animals and humans. Rev. Infect. Dis. 9, S43–S46 (1987).

    Google Scholar 

64. Lestner, J. M. et al. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin. Infect. Dis. 49, 928–930 (2009).

    Google Scholar 

65. Shim, J. S. et al. Divergence of antiangiogenic activity and hepatotoxicity of different stereoisomers of itraconazole. Clin. Cancer Res. 22, 2709–2720 (2016).

    Google Scholar 

66. Wörn, A. & Plückthun, A. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305, 989–1010 (2001).

    Google Scholar 

67. Röthlisberger, D., Honegger, A. & Plückthun, A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 347, 773–789 (2005).

    Google Scholar 

68. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

    Google Scholar 

69. Sommermeyer, D. et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 31, 2191–2199 (2017).

    Google Scholar 

70. Ghorashian, S. et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat. Med. 25, 1408–1414 (2019).

    Google Scholar 

71. Lavrsen, K. et al. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj. J. 30, 227–236 (2013).

    Google Scholar 

72. Macías-León, J. et al. Structural characterization of an unprecedented lectin-like antitumoral anti-MUC1 antibody. Chem. Commun. 56, 15137–15140 (2020).

    Google Scholar 

73. Wang, S., You, L., Dai, M. & Zhao, Y. Mucins in pancreatic cancer: a well-established but promising family for diagnosis, prognosis and therapy. J. Cell Mol. Med. 24, 10279–10289 (2020).

    Google Scholar 

74. Sanchez, J.-F. et al. Biochemical and structural analysis of Helix pomatia agglutinin. A hexameric lectin with a novel fold. J. Biol. Chem. 281, 20171–20180 (2006).

    Google Scholar 

75. Radhakrishnan, P. et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc. Natl. Acad. Sci. USA 111, E4066–E4075 (2014).

    Google Scholar 

76. Itzkowitz, S. et al. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 100, 1691–1700 (1991).

    Google Scholar 

77. Barr, N., Taylor, C. R., Young, T. & Springer, G. F. Are pancarcinoma T and Tn differentiation antigens? Cancer 64, 834–841 (1989).

    Google Scholar 

78. Bulteau, F. et al. Targeting Tn-antigen-positive human tumors with a recombinant human macrophage galactose C-type lectin. Mol. Pharm. 19, 235–245 (2022).

    Google Scholar 

79. Lenza, M. P. et al. Structural insights into Siglec-15 reveal glycosylation dependency for its interaction with T cells through integrin CD11b. Nat. Commun. 14, 3496 (2023).

    Google Scholar 

80. Dobrin, A. et al. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies. Nat. Cancer 5, 760–773 (2024).

    Google Scholar 

81. McKenna, M. K. et al. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma. J. Immunother. Cancer 11, e005891 (2023).

    Google Scholar 

82. Del Bufalo, F. et al. GD2-CART01 for Relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284–1295 (2023).

    Google Scholar 

83. Meléndez, A. V. et al. Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells. Cell Mol. Life Sci. 79, 513 (2022).

    Google Scholar 

84. Malaker, S. A. et al. The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins. Proc. Natl. Acad. Sci. USA 116, 7278–7287 (2019).

    Google Scholar 

85. Hirao, T., Sakamoto, Y., Kamada, M., Hamada, S. & Aono, T. Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 72, 154–159 (1993).

    Google Scholar 

86. Terasawa, K., Furumoto, H., Kamada, M. & Aono, T. Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells. Cancer Res. 56, 2229–2232 (1996).

    Google Scholar 

87. Byrd, J. C. & Bresalier, R. S. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23, 77–99 (2004).

    Google Scholar 

88. Hagerty, B. et al. Novel humanized mesothelin-expressing genetically engineered mouse models underscore challenges in delivery of complex therapeutics to pancreatic cancers. Mol. Cancer Ther. 20, 2082–2092 (2021).

    Google Scholar 

89. Zervos, E., Agle, S., Freistaedter, A. G., Jones, G. J. B. & Roper, R. L. Murine mesothelin: characterization, expression, and inhibition of tumor growth in a murine model of pancreatic cancer. J. Exp. Clin. Cancer Res. 35, 39 (2016).

    Google Scholar 

Download references